PCI Biotech Holding ASA (FRA:4QG)

Germany flag Germany · Delayed Price · Currency is EUR
0.0180
+0.0004 (2.27%)
At close: Dec 4, 2025
-85.15%
Market Cap 799.51K
Revenue (ttm) 394.60K
Net Income (ttm) -1.73M
Shares Out n/a
EPS (ttm) -0.05
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume n/a
Average Volume n/a
Open 0.0180
Previous Close 0.0176
Day's Range 0.0180 - 0.0180
52-Week Range 0.0176 - 0.1505
Beta n/a
RSI 39.67
Earnings Date Nov 18, 2025

About PCI Biotech Holding ASA

PCI Biotech Holding ASA, a biopharmaceutical company, focuses on the development of technologies and novel therapies through its photochemical technology platform. The company’s technology platform consists of a proprietary small molecule photosensitiser and a light source; and develops photochemical lysis (PCL) comprising light-triggered cell lysis, which enhances yield and purity in viral vector manufacturing, as well as photochemical internalisation (PCI), inducing light-triggered intracellular release for various therapeutic modalities. It ... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2007
Employees 5
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol 4QG
Full Company Profile

Financial Performance

In 2024, PCI Biotech Holding ASA's revenue was 6.74 million, an increase of 125.25% compared to the previous year's 2.99 million. Losses were -16.42 million, -19.19% less than in 2023.

Financial numbers in NOK Financial Statements

News

There is no news available yet.